©2024 Stanford Medicine
Antibiotic Prophylaxis in Rhinoplasty
Recruiting
I'm InterestedTrial ID: NCT04194216
Purpose
This study compares the efficacy of a single intra-operative (intravenous) dose of
"cephalexin" (first generation cephalosporin) or "clindamycin" (lincosamides), alone versus
both intra-operative (intravenous) dose of "cephalexin" (first generation cephalosporin) or
"clindamycin" (lincosamides) and postoperative oral dose of "cephalexin" or "clindamycin" use
in nasal surgery.
Official Title
Comparison of Outcomes in Rhinoplasty With the Use of Intraoperative Versus Postoperative Antibiotics
Stanford Investigator(s)
Sam P. Most, MD, FACS
Professor of Otolaryngology - Head & Neck Surgery (OHNS)
Eligibility
Inclusion Criteria:
Adult patients (aged 18years and older)
Exclusion Criteria:
- Prior rhinoplasty
- Any exogenous (non-nasal) grafts/implants
- Immune deficiency (DM, meds, other)
- History of radiotherapy to nose
Intervention(s):
drug: Intra-operative single intravenous(iv) dose of "cephalexin" 2 g or "clindamycin" 900 mg.
drug: Intra-operative single dose (iv) of "cephalexin" 2 g or "clindamycin" 900 mg and postoperative oral dose of "cephalexin" 250mg (every 4 hours) or "clindamycin" 150mg(every 6 hours) for 3 days
Recruiting
I'm InterestedContact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Sam P Most, MD
6507363223